Jasper Therapeutics, Inc. (JSPR): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2020-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$31.63M

As of 2025-12-31

$10.39M

As of 2026-06-30

+36.7%

3-year compound annual growth

+16.6%

5-year compound annual growth

2019-12-31 Total Liabilities (USD) 2025-12-31

Period ended	Total Liabilities	Change YoY	Source filing
2025-12-31	$31.63M	+73.5%	2026-03-30, Balance as of period end
2024-12-31	$18.23M	+10.8%	2026-03-30, Balance as of period end
2023-12-31	$16.45M	+33.0%	2025-02-28, Balance as of period end
2022-12-31	$12.37M	-48.7%	2024-03-05, Balance as of period end
2021-12-31	$24.14M	+64.8%	2023-03-08, Balance as of period end
2020-12-31	$14.65M	n/c	2022-03-18, Balance as of period end
2019-12-31	$10.85M	n/a	2021-05-24, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Total Liabilities	Change YoY
Jasper Therapeutics, Inc. (JSPR)	2025-12-31	$31.63M	+73.5%
Inmune Bio, Inc. (INMB)	2025-12-31	$8.83M	+18.2%
IN8BIO, Inc. (INAB)	2025-12-31	$4.72M	-26.9%
Ocugen, Inc. (OCGN)	2025-12-31	$55.68M	+5.4%
CEL SCI Corp (CVM)	2025-09-30	$12.20M	-13.6%
Windtree Therapeutics Inc (WINT)	2024-12-31	$14.70M	-49.3%
PharmaCyte Biotech, Inc. (PMCB)	2026-04-30	$11.77M	+259.2%
Champions Oncology, Inc. (CSBR)	2026-04-30	$22.92M	-19.8%
Cognition Therapeutics Inc (CGTX)	2025-12-31	$14.12M	+22.9%

Compare JSPR, INMB, INAB, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗